Feb 08, 2019 - AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.
Feb 08, 2019 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2018 Results Earnings Conference Call February 07, 2019, 04:30 PM ET Company Participants Todd Pettingill - Director, Corporate Development and Inv
Feb 06, 2019 - Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.
Jan 28, 2019 -
Jan 05, 2019 - Ligand Pharmaceuticals is an interesting and diverse play on growth of the pharmaceutical industry.I like the interesting business model, as Ligand appears to have a very rich pipeline.A very strong m
Jan 04, 2019 - Amid the current bear market, many fundamentally sound companies are on sale at a deep bargain. Hence, we are continually on the hunt for high-quality stocks.Ligand Pharmaceuticals is an excellent bar
Nov 26, 2018 - VK-2809 has neither clinical data nor an IND in NASH and its development lags 2.5 - 3 years behind MGL-3196.Even if successful in a NASH trial, VK-2809 will be competing in a crowded space with variou
Nov 08, 2018 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2018 Earnings Conference Call November 08, 2018 09:00 AM ET Executives Todd Pettingill - Director, Corporate Development and Investor Relations Joh
Nov 08, 2018 - Ligand (LGND) delivered earnings and revenue surprises of 33.33% and 7.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Nov 06, 2018 - Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.